AtriCure (ATRC) extends $125M ABL credit facility and cuts interest rate

Rhea-AI Filing Summary

AtriCure, Inc. entered into a First Amendment to its credit agreement with JPMorgan Chase Bank and other lenders, extending the term of its asset-based revolving credit facility by three years. The amended credit agreement maintains an asset-based revolving credit facility of up to $125 million, with the option to increase commitments by up to $40 million, for a potential total of $165 million. A portion of the facility not exceeding $5 million is available for letters of credit, and swingline loans may be advanced at the Administrative Agent’s discretion. The amendment also reduces the overall interest rate on loans under the facility and removes the minimum utilization financial covenant. The facility is secured by a first priority security interest in substantially all borrower assets and is guaranteed by the company and its material domestic subsidiaries, and it will be used to finance working capital and general corporate purposes.

Insights

Capital structure and credit facilities analyst

AtriCure extends and reprices its asset-based revolver on more favorable terms.

AtriCure amended its credit agreement with JPMorgan and other lenders, keeping an asset-based revolving facility of up to $125 million and extending the term by three years. The facility can be increased by up to $40 million to a total of $165 million, with a $5 million sublimit for letters of credit and availability for swingline loans advanced by the Administrative Agent.

The amendment reduces the overall interest rate on borrowings under the ABL facility and removes a minimum utilization financial covenant, while leaving the facility secured by a first priority security interest in substantially all borrower assets and guaranteed by material domestic subsidiaries. These changes adjust pricing and covenant structure but keep the overall secured, asset-based framework in place.

The facility is designated for working capital and general corporate purposes, so actual usage will depend on operational needs. Preliminary fourth quarter and full-year 2025 financial results are referenced via a separate press release dated January 12, 2026, indicating that more detailed performance information is being shared outside this summary.

8-K Event Classification

4 items: 1.01, 2.02, 2.03, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001323885 0001323885 2026-01-09 2026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 9, 2026

AtriCure, Inc.

(Exact name of registrant as specified in charter)

Delaware		000-51470		34-1940305
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7555 Innovation Way, Mason OH 45040

(Address of Principal Executive Offices, and Zip Code)

(513) 755-4100

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $.001 par value		ATRC		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On January 9, 2026 (the “Closing Date”), AtriCure, Inc. (the “Company”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “Borrowers”), entered into a First Amendment (“First Amendment”) to Credit Agreement (as amended, the “Credit Agreement”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), JPMorgan Chase Bank, N.A., as bookrunner and lead arranger (“JPMCB”), and the lenders party thereto (“Lenders”). The First Amendment provides for a three year extension of the term of the Credit Agreement. The First Amendment also provides for a reduction in the overall interest rate on the loans under the ABL Facility and removes the minimum utilization financial covenant in addition to certain other loan administration updates.

The Credit Agreement provides for an asset-based revolving credit facility (the “ABL Facility”) in an amount of up to $125 million. Borrowers may, at their option, and subject to customary conditions, request an increase in the revolving commitment by up to $40 million (not to exceed a total of $165 million) by obtaining additional commitments from one or more Lenders or with the consent of JPMCB. A portion of the ABL Facility not in excess of $5 million is available for the issuance of letters of credit in U.S. dollars by JPMCB or other financial institutions. The Administrative Agent, in its sole discretion, may create swingline loans (the “Swingline Loans”) by advancing to the Borrowers, on behalf of the Lenders, floating rate revolving loans requested by Borrowers. Any such Swingline Loans will reduce availability under the ABL Facility on a dollar-for-dollar basis.

The ABL Facility will be used to finance the Company’s working capital needs and for general corporate purposes.

The ABL Facility is secured by a first priority perfected security interest (subject to customary exceptions) in all of the assets of the Borrowers, whether consisting of personal, tangible or intangible property, including all of the outstanding equity interests of the Company’s direct subsidiaries (limited, in the case of foreign subsidiaries, to less than 65% of the equity interest of such foreign subsidiaries to the extent a pledge or greater percentage could reasonably be expected to (i) cause the undistributed earnings of such foreign subsidiary to be treated as a deemed dividend to such foreign subsidiary’s parent and (ii) result in material adverse tax consequences). Each Borrower and each direct and indirect Material Domestic Subsidiary of the Company (each a “Guarantor”) has unconditionally guaranteed all of the indebtedness, obligations and liabilities of the Borrowers arising under the ABL Facility. At the time of closing the ABL Facility, the Borrowers are the only Guarantors.

The above description of the First Amendment and Credit Agreement is not complete and is qualified in its entirety by the actual terms of the First Amendment and Credit Agreement. A copy of the First Amendment is filed herewith as Exhibit 10.1 and is incorporated herein by reference. A copy of the Credit Agreement is filed as Exhibit 10.1 with our Current Report on Form 8-K filed on January 8, 2024 and is incorporated herein by reference.

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, AtriCure issued a press release announcing its preliminary financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

The information in Item 2.02 of this Form 8-K and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Form 8-K and Exhibit 99.1 shall not be incorporated by reference in any filing (whether made before or after the date hereof) or any other document under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing or document.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

No.		Description
10.1		First Amendment to JPMorgan Credit Agreement*
99.1		Press Release dated January 12, 2026
104		Cover Page Interactive Data File—the cover page XBRL tags are embedded within the Inline XBRL document.

* Certain of the exhibits and schedules to these exhibits have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish copies of any of the omitted exhibits and schedules to the SEC upon its request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				ATRICURE, INC.
Dated: January 12, 2026				By:		/s/ Angela L. Wirick
						Angela L. Wirick
						Chief Financial Officer

FAQ

What did AtriCure (ATRC) change in its credit agreement?

AtriCure and its subsidiary entered into a First Amendment to their credit agreement with JPMorgan and other lenders. The amendment provides for a three-year extension of the term, a reduction in the overall interest rate on loans under the asset-based revolving facility, removal of the minimum utilization financial covenant, and certain loan administration updates.

How large is AtriCure's asset-based revolving credit facility under the amended agreement?

The amended credit agreement provides for an asset-based revolving credit facility of up to $125 million. AtriCure may, at its option and subject to customary conditions, request up to an additional $40 million in revolving commitments, for a potential total facility size of $165 million.

What are the key features of the AtriCure (ATRC) ABL Facility, including letters of credit and swingline loans?

Under the ABL Facility, up to $5 million is available for letters of credit in U.S. dollars issued by JPMorgan or other financial institutions. The Administrative Agent may also create Swingline Loans by advancing floating rate revolving loans on behalf of the lenders, and any such swingline borrowings reduce availability under the ABL Facility on a dollar-for-dollar basis.

How is AtriCure's amended credit facility secured and guaranteed?

The ABL Facility is secured by a first priority perfected security interest in substantially all of the borrowers’ assets, including equity in direct subsidiaries, subject to customary exceptions and limitations on pledges of foreign subsidiary equity. Each borrower and each material domestic subsidiary serves as a guarantor, unconditionally guaranteeing all indebtedness and obligations arising under the facility.

What will AtriCure use the ABL Facility for?

AtriCure states that the ABL Facility will be used to finance the company’s working capital needs and for general corporate purposes, providing access to revolving borrowing capacity as needed for operations.

Did AtriCure announce any financial results in connection with this 8-K?

AtriCure disclosed that on January 12, 2026 it issued a press release announcing its preliminary financial results for the fourth quarter and full year ended December 31, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference, while the specific financial figures are not detailed in this summary.